These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 28051838)

  • 1. Mixed-amphetamine salts increase abstinence from marijuana in patients with co-occurring attention-deficit/hyperactivity disorder and cocaine dependence.
    Notzon DP; Mariani JJ; Pavlicova M; Glass A; Mahony AL; Brooks DJ; Grabowski J; Levin FR
    Am J Addict; 2016 Dec; 25(8):666-672. PubMed ID: 28051838
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Extended-Release Mixed Amphetamine Salts vs Placebo for Comorbid Adult Attention-Deficit/Hyperactivity Disorder and Cocaine Use Disorder: A Randomized Clinical Trial.
    Levin FR; Mariani JJ; Specker S; Mooney M; Mahony A; Brooks DJ; Babb D; Bai Y; Eberly LE; Nunes EV; Grabowski J
    JAMA Psychiatry; 2015 Jun; 72(6):593-602. PubMed ID: 25887096
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of mixed amphetamine salts extended release (Adderall XR) in the management of attention-deficit/hyperactivity disorder in adolescent patients: a 4-week, randomized, double-blind, placebo-controlled, parallel-group study.
    Spencer TJ; Wilens TE; Biederman J; Weisler RH; Read SC; Pratt R
    Clin Ther; 2006 Feb; 28(2):266-79. PubMed ID: 16678648
    [TBL] [Abstract][Full Text] [Related]  

  • 4. How treatment improvement in ADHD and cocaine dependence are related to one another: A secondary analysis.
    Levin FR; Choi CJ; Pavlicova M; Mariani JJ; Mahony A; Brooks DJ; Nunes EV; Grabowski J
    Drug Alcohol Depend; 2018 Jul; 188():135-140. PubMed ID: 29775957
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of mixed amphetamine salts extended release (adderall XR) in the management of oppositional defiant disorder with or without comorbid attention-deficit/hyperactivity disorder in school-aged children and adolescents: A 4-week, multicenter, randomized, double-blind, parallel-group, placebo-controlled, forced-dose-escalation study.
    Spencer TJ; Abikoff HB; Connor DF; Biederman J; Pliszka SR; Boellner S; Read SC; Pratt R
    Clin Ther; 2006 Mar; 28(3):402-18. PubMed ID: 16750455
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A post hoc subgroup analysis of an 18-day randomized controlled trial comparing the tolerability and efficacy of mixed amphetamine salts extended release and atomoxetine in school-age girls with attention-deficit/hyperactivity disorder.
    Biederman J; Wigal SB; Spencer TJ; McGough JJ; Mays DA
    Clin Ther; 2006 Feb; 28(2):280-93. PubMed ID: 16678649
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mixed amphetamine salts extended-release in the treatment of adult ADHD: a randomized, controlled trial.
    Weisler RH; Biederman J; Spencer TJ; Wilens TE; Faraone SV; Chrisman AK; Read SC; Tulloch SJ
    CNS Spectr; 2006 Aug; 11(8):625-39. PubMed ID: 16871129
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Health care costs of adults treated for attention-deficit/hyperactivity disorder who received alternative drug therapies.
    Wu EQ; Birnbaum HG; Zhang HF; Ivanova JI; Yang E; Mallet D
    J Manag Care Pharm; 2007 Sep; 13(7):561-9. PubMed ID: 17874862
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A randomized, double-blind, 3-way crossover, analog classroom study of SHP465 mixed amphetamine salts extended-release in adolescents with ADHD.
    Wigal S; Lopez F; Frick G; Yan B; Robertson B; Madhoo M
    Postgrad Med; 2019 Apr; 131(3):212-224. PubMed ID: 30681017
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Post-Hoc Analyses of the Effects of Baseline Sleep Quality on SHP465 Mixed Amphetamine Salts Extended-Release Treatment Response in Adults with Attention-Deficit/Hyperactivity Disorder.
    Surman CBH; Robertson B; Chen J; Cortese S
    CNS Drugs; 2019 Jul; 33(7):695-706. PubMed ID: 31228031
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and Safety of SHP465 Mixed Amphetamine Salts in the Treatment of Attention-Deficit/Hyperactivity Disorder in Adults: Results of a Randomized, Double-Blind, Placebo-Controlled, Forced-Dose Clinical Study.
    Weisler RH; Greenbaum M; Arnold V; Yu M; Yan B; Jaffee M; Robertson B
    CNS Drugs; 2017 Aug; 31(8):685-697. PubMed ID: 28712074
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An open-label study of the tolerability of mixed amphetamine salts in adults with attention-deficit/hyperactivity disorder and treated primary essential hypertension.
    Wilens TE; Zusman RM; Hammerness PG; Podolski A; Whitley J; Spencer TJ; Gignac M; Biederman J
    J Clin Psychiatry; 2006 May; 67(5):696-702. PubMed ID: 16841618
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Attention-deficit/hyperactivity disorder-specific quality of life with triple-bead mixed amphetamine salts (SPD465) in adults: results of a randomized, double-blind, placebo-controlled study.
    Spencer TJ; Landgraf JM; Adler LA; Weisler RH; Anderson CS; Youcha SH
    J Clin Psychiatry; 2008 Nov; 69(11):1766-75. PubMed ID: 19026251
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A randomized, double-blind study of SHP465 mixed amphetamine salts extended-release in adults with ADHD using a simulated adult workplace design.
    Wigal T; Brams M; Frick G; Yan B; Madhoo M
    Postgrad Med; 2018 Jun; 130(5):481-493. PubMed ID: 29809075
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of SHP465 mixed amphetamine salts in adults with ADHD in a simulated adult workplace environment.
    Wigal T; Childress A; Frick G; Yan B; Wigal S; Madhoo M
    Postgrad Med; 2018 Jan; 130(1):111-121. PubMed ID: 29087231
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Medication adherence and symptom reduction in adults treated with mixed amphetamine salts in a randomized crossover study.
    Adler LA; Lynch LR; Shaw DM; Wallace SP; Ciranni MA; Briggie AM; Kulaga A; O'Donnell KE; Faraone SV
    Postgrad Med; 2011 Sep; 123(5):71-9. PubMed ID: 21904088
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Stimulant therapy in the management of ADHD: mixed amphetamine salts (extended release).
    Faraone SV
    Expert Opin Pharmacother; 2007 Sep; 8(13):2127-34. PubMed ID: 17714065
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sustained release methylphenidate for the treatment of ADHD in amphetamine abusers: a pilot study.
    Konstenius M; Jayaram-Lindström N; Beck O; Franck J
    Drug Alcohol Depend; 2010 Apr; 108(1-2):130-3. PubMed ID: 20015599
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Medication use in adults with attention deficit/hyperactivity disorder in a commercially-insured population in the United States.
    Zhou Z; Zhou ZY; Kelkar SS; Sikirica V; Xie J; Grebla R
    Curr Med Res Opin; 2018 Apr; 34(4):585-592. PubMed ID: 29186993
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An interim analysis of the Quality of Life, Effectiveness, Safety, and Tolerability (QU.E.S.T.) evaluation of mixed amphetamine salts extended release in adults with ADHD.
    Goodman DW; Ginsberg L; Weisler RH; Cutler AJ; Hodgkins P
    CNS Spectr; 2005 Dec; 10(12 Suppl 20):26-34. PubMed ID: 16344838
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.